Taiki Takahashi is a focused and analytically driven student with strong interests in finance, global economics, and quantitative reasoning. Known for his steady work ethic and thoughtful insights, he brings clarity and precision to group discussions and team projects. Outside the classroom, Taiki enjoys studying market trends, strengthening his technical skills, and exploring long-term investment themes.

Soleno Therapeutics develops therapies for rare metabolic disorders, led by VYKAT XR — the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome. The company sits at the center of an underserved, high-need market with strong regulatory momentum and clear clinical differentiation. With commercial rollout accelerating and a highly focused pipeline, Soleno trades at a discount to its orphan-drug peers despite a de-risked profile. The upside case is continued adoption and expanding PWS market penetration driving a rerating as SLNO becomes a pure-play rare-disease growth story.